Cystic fibrosis is caused by mutations in the CFTR gene, which encodes a protein that regulates the transport of chloride and sodium ions across cell membranes. When this protein is absent or dysfunctional, the result is thick, sticky mucus that accumulates in the lungs, digestive system, liver, and other organs.

More than 2,000 CFTR mutations have been identified, though a relatively small number account for the majority of cases. The F508del mutation, the most common CF mutation globally, accounts for approximately 70% of CF alleles worldwide, according to the Cystic Fibrosis Mutation Database.

The consequences of CFTR dysfunction extend well beyond mucus accumulation:

• Chronic pulmonary infection: Thick mucus creates an ideal environment for bacterial colonisation, particularly by Pseudomonas aeruginosa and Staphylococcus aureus. Chronic infection becomes established in most CF patients during childhood and drives progressive lung damage
• Bronchiectasis: permanent structural widening and scarring of the airways resulting from repeated cycles of infection and inflammation. According to a study published in the European Respiratory Journal, bronchiectasis is present in the majority of CF patients by early adulthood and is a primary driver of lung function decline
• Pancreatic insufficiency: CFTR dysfunction impairs pancreatic enzyme secretion in approximately 85–90% of CF patients, leading to malabsorption, malnutrition, and CF-related diabetes
• Liver disease: Biliary obstruction and progressive liver fibrosis affect a significant minority of CF patients, with CF-related liver disease being a leading cause of non-pulmonary mortality
• Chronic sinusitis: Persistent sinus infection and inflammation affecting quality of life and acting as a bacterial reservoir
• Bone disease: Reduced bone mineral density is common in CF due to malabsorption, chronic inflammation, and corticosteroid use, increasing fracture risk
• Fertility complications: The majority of males with CF are infertile due to congenital absence of the vas deferens

The median predicted survival age for CF patients has improved substantially, from under 30 years in the 1990s to over 50 years in high-income countries with access to modern treatment, according to the Cystic Fibrosis Foundation Patient Registry. However, this improvement is uneven, and a significant proportion of patients continue to experience rapid progression despite optimal conventional care.

Standard Cystic Fibrosis care has advanced considerably, and for eligible patients, CFTR modulators represent a genuine step forward. But the treatment landscape still leaves meaningful gaps, particularly for patients with a disease that has progressed despite available therapy.

The fundamental limitation: Standard care manages CF effectively in many patients, but does not address several of the biological processes driving progression, specifically the chronic inflammatory state, the immune dysregulation that perpetuates lung damage, and the tissue destruction that accumulates over years.

MSC therapy for cystic fibrosis is not gene therapy. It does not insert a functional CFTR gene or correct the underlying mutation. What it offers is a different angle of attack, reducing the inflammatory and immune-driven damage that turns a genetic abnormality into progressive organ destruction.

The Science Behind Mesenchymal Stem Cells (MSCs)

GS Medical Services coordinates treatment at specialist clinics in Germany that use mesenchymal stem cells derived from ethically sourced donors. In the context of cystic fibrosis, MSCs have been shown to:

• Secrete potent anti-inflammatory cytokines, that reduce the chronic pulmonary inflammatory state driving airway damage in CF lungs
• Modulate neutrophil activity, the excessive neutrophil-dominated inflammation characteristic of CF airways releases proteases such as neutrophil elastase that destroy lung tissue. MSCs reduce this destructive inflammatory activity
• Support airway epithelial repair, MSC-derived growth factors promote the regeneration of damaged airway epithelial cells, partially restoring barrier function
• Reduce pulmonary fibrosis, MSCs have demonstrated anti-fibrotic properties in preclinical lung injury models, potentially slowing the progressive scarring that drives irreversible lung function decline in CF
• Modulate the immune response to chronic bacterial infection, rather than further suppressing immune defences, MSCs appear to shift the immune environment toward a more regulated state that reduces collateral tissue damage without compromising pathogen defence
• Improve mitochondrial function in airway cells, mitochondrial dysfunction has been identified as a contributing factor in CF airway inflammation; MSC-derived signals may support cellular energy production in affected tissues

A 2021 review published in Stem Cell Reviews and Reports noted that MSC therapy has shown promise in preclinical CF models, with particular evidence for anti-inflammatory and pro-regenerative effects in airway tissue, supporting its rationale as a complementary approach alongside existing CFTR-targeting therapies.

Potential Mechanisms of Action in Cystic Fibrosis

• Neutrophil elastase reduction: Neutrophil elastase is a highly damaging substance in CF lungs. It breaks down lung tissue, disrupts mucus clearance, and harms airway walls. MSCs help by reducing signals (such as IL-8) that attract and activate neutrophils, thereby tackling a major cause of lung damage.
• IL-17 pathway modulation: IL-17 is an inflammatory cytokine that attracts more neutrophils and sustains inflammation in CF lungs. MSC therapy can reduce IL-17 activity, helping to calm this cycle.
• Airway epithelial repair: In CF, the airway lining is constantly damaged. MSCs release growth factors that help repair and regenerate this lining, improving airway structure and function.
• Macrophage polarisation: Immune cells called macrophages in CF tend to promote inflammation. MSCs shift them toward a healing, anti-inflammatory state, supporting tissue repair and reducing ongoing inflammation.
• Systemic anti-inflammatory effect: CF affects more than just the lungs. Widespread inflammation can impact bones, the liver, and overall health. MSC therapy may help reduce inflammation throughout the body, not just in the lungs.

Important consideration: Stem cell therapy for cystic fibrosis is not a cure and does not correct the CFTR mutation. Outcomes vary considerably between individuals and depend on mutation type, degree of lung and organ involvement, age, current treatment, and individual biological response. GS Medical Services is committed to providing an honest assessment of what this treatment may and may not offer each patient.

A structured cellular therapy programme is designed specifically for international and regional patients. Every step is coordinated by a dedicated team.

Step 1: Comprehensive Medical Review and Eligibility Assessment

Your journey begins with a thorough evaluation:

• Full review of medical history, CFTR mutation genotype, current lung function (FEV1, FVC), infection history, and organ involvement
• Assessment of current treatment, including CFTR modulators, inhaled therapies, and nutritional status
• In-depth consultation with the medical team
• Honest assessment of whether you or your child is a suitable candidate, including a direct answer if the evidence does not support treatment in your case

Step 2: Personalised Treatment Planning

If assessed as a suitable candidate, a fully individualised protocol is developed:

• Protocol tailored to CFTR genotype, degree of pulmonary and systemic involvement, current treatment regimen, age, and overall health
• Clear explanation of the procedure, expected timeline, and realistic outcome expectations
• Transparent discussion of potential benefits, risks, and how MSC therapy fits alongside existing CF treatment
• Comprehensive logistics support, including travel arrangements and accommodation guidance for international patients

Step 3: Cellular Therapy Procedure

Treatment is conducted by experienced, licensed physicians in a clinical environment meeting international medical standards:

• Minimally invasive procedure, typically administered intravenously (IV), allowing MSCs to circulate systemically and home to sites of inflammation and tissue damage, particularly in the lungs
• Outpatient basis; patients can return to their accommodation the same day
• Sterile clinical environment with full infection control protocols, particularly important given CF patients' susceptibility to infection
• Physician-supervised throughout, with immediate post-treatment monitoring
• Local anaesthesia or sedation where required

The procedure typically takes 2-4 hours, including preparation and post-procedure observation.

Step 4: Structured Follow-Up and Progress Monitoring

Your care extends well beyond the treatment procedure:

• Remote follow-up via secure telemedicine, no need to return to Germany for routine reviews
• Progress evaluation using spirometry, inflammatory markers, exacerbation frequency, and patient-reported outcome measures to track changes over time
• Personalised guidance on airway clearance, nutritional strategies, and ongoing medical management to complement the cellular therapy
• Long-term monitoring to assess the durability of any treatment benefit
• Direct access to the medical team throughout, for questions or concerns as they arise

MSC therapy is not appropriate for every CF patient. Those most likely to benefit typically share the following profile:

• Confirmed diagnosis of cystic fibrosis (CF) with lung or other organ involvement
• Ongoing symptoms, frequent flare-ups, or worsening lung function despite standard treatment (including CFTR modulators, if suitable)
• Patients who cannot access CFTR modulators, cannot tolerate them, or get only limited benefit
• Lung function (FEV1) is generally above 30–35%; very advanced cases are assessed individually for safety
• No active lung infection or flare-up at the time of treatment; condition should be stable
• Overall health and nutrition should be reasonably good
• A clear understanding that MSC therapy does not fix the underlying genetic defect
• Willingness to continue regular CF treatments before and after MSC therapy

Children, adolescents, and adults are all assessed individually. Earlier intervention, before significant irreversible structural lung damage has accumulated, generally offers the best prospect for meaningful benefit.

Based on current clinical research, preclinical evidence, and emerging patient outcomes, MSC therapy for CF may offer the following benefits. Outcomes are not guaranteed and vary between individuals.

• Reduced pulmonary exacerbation frequency: Reduction in the chronic inflammatory environment may decrease the frequency and severity of acute pulmonary exacerbations, the episodes that drive the most significant lung function decline in CF
• Slowed lung function decline: By addressing the inflammatory and fibrotic processes driving airway destruction, MSC therapy may help slow the rate of FEV1 decline, the primary measure of CF progression
• Reduced airway inflammation: Measurable reductions in inflammatory markers have been observed in MSC therapy studies in other inflammatory lung conditions, with relevance to the CF context
• Improved respiratory symptoms: Some patients report improvements in breathlessness, sputum production, and exercise tolerance following treatment
• Systemic anti-inflammatory benefit: Reduced systemic inflammation may contribute to improvements in bone health, liver function, and general wellbeing beyond the lungs
• Improved quality of life: Reduced exacerbation frequency, better respiratory symptoms, and improved energy combine to produce meaningful improvements in daily life for some patients
• Complementary benefit alongside CFTR modulators: For patients already on modulator therapy, MSC treatment may address the residual inflammatory burden that modulators do not target, providing benefit at a different biological level

Research published in peer-reviewed journals has reported anti-inflammatory and pro-regenerative effects of MSC therapy in pulmonary conditions sharing key pathological features with CF. The field continues to develop, and GS Medical Services works with clinics that adhere to evidence-informed treatment protocols.

Stem cell therapy has a well-documented safety record when performed correctly in appropriate clinical settings. Like any medical procedure, it carries risks that will be discussed in full during your consultation. CF patients require particular attention to infection risk during pre-procedure planning.

Common side effects (typically mild and temporary):

• Temporary fatigue or mild headache following treatment
• Low-grade fever for 24-48 hours post-procedure, important to distinguish from a pulmonary exacerbation in CF patients; guidance is provided
• Mild discomfort or bruising at the infusion site
• Temporary increase in respiratory symptoms in the first 1-2 weeks, which generally resolves on its own

Rare but serious complications:

• Infection; CF patients carry an elevated baseline infection risk; stringent infection control protocols are in place, and the procedure is not performed during active exacerbations
• Allergic reaction to procedure components
• Thromboembolic events are very rare cases, carefully screened for during pre-treatment assessment

Every patient undergoes thorough pre-procedure screening before treatment begins, with CF-specific considerations, including microbiology status, lung function, and nutritional assessment, incorporated into the risk evaluation.

Post-Treatment Guidance: All patients receive comprehensive post-treatment instructions, including guidance on continuing airway clearance routines, continuing all existing CF medications, warning signs to distinguish normal post-procedure responses from CF exacerbations, and nutritional recommendations to support recovery.

Cystic Fibrosis is a condition that demands a great deal from patients and families, daily treatment routines, frequent medical appointments, the emotional weight of managing a progressive condition. Adding an international treatment to that picture is not a decision taken lightly. GS Medical Services exists to make that process as straightforward and well-supported as it can be, here’s what we offer:

• German Clinical Excellence: All treatment is delivered through clinics operating under Germany's rigorous national medical standards, guided by evidence-informed protocols from Europe's leading centres for integrative and biological medicine.
• Personalised Treatment Plans: CF presentations vary significantly depending on genotype, mutation class, degree of lung involvement, and treatment history. Every protocol is built around the individual patient's specific clinical picture, not a standard package.
• Compassionate & Expert Care: Families managing CF have often spent years navigating a demanding treatment landscape. Our physicians and coordinators understand that. Consultations are direct, unhurried, and honest, including when MSC therapy is unlikely to be the right fit.
• International Patient Support: Scheduling, documentation, clinic communication, and accommodation guidance, all coordinated, with particular attention to the practical needs of CF patients travelling internationally.
• Transparency & Honest Guidance: MSC therapy for CF has a specific evidence base and a specific patient profile it is most likely to help. We are clear about both. If your case does not meet the criteria, we say so at the consultation.
• Continuity of Care: Structured telemedicine follow-up, pulmonary function monitoring, and direct access to the medical team continue well after you return home.

If you or a family member has cystic fibrosis and is exploring options beyond standard care, a comprehensive medical evaluation is a sensible next step. You may consult Dr. Med. Gerhard Siebenhüner for an expert assessment and personalised treatment guidance.

Your initial consultation covers:

• A confidential review of medical records, CFTR genotype, lung function history, and current treatment
• A straight assessment of whether MSC therapy is appropriate for your specific case, including an honest answer if it is not
• A grounded conversation about what improvement may look like, what the risks are, and what outcomes are realistically possible
• A full walkthrough of the procedure, timeline, and what travelling to Germany involves practically
• Complete pricing breakdown upfront, with no hidden costs
• As much time as you need to ask questions

Proceeding after the consultation is entirely your decision. What we can offer is enough information to make a considered choice, and the space to make it without pressure.

Does MSC therapy replace CFTR modulators like Trikafta?
No. MSC therapy and CFTR modulators work at entirely different biological levels. Modulators target the dysfunctional CFTR protein directly, improving its function where possible. MSC therapy addresses the inflammatory and immune-driven tissue damage that modulators do not target. 

Is MSC therapy suitable for CF patients who do not respond to CFTR modulators?
Yes. Patients whose mutations do not qualify for or respond to current modulators still face the full inflammatory and immune burden of CF. MSC therapy's mechanisms, anti-inflammatory signalling, airway epithelial support, immune modulation, are relevant regardless of CFTR mutation class.

Can children with cystic fibrosis receive MSC therapy?
Children are assessed individually. Earlier intervention, before significant irreversible structural lung damage has accumulated, generally offers the best prospect for meaningful benefit. Age, weight, nutritional status, and lung function are all considered during the assessment process.

Is there a risk of infection during the stem cell therapy treatment for Cystic Fibrosis?
This is taken very seriously. Treatment is not performed during active pulmonary exacerbations, and stringent infection control protocols are in place throughout. Pre-procedure microbiology assessment is part of the standard evaluation to ensure the clinical environment is appropriate for each individual patient.

How is stem cell therapy regulated in Germany?
In Germany, stem cell therapies are strictly regulated and must comply with national medical and safety standards. Treatment is performed in licensed clinical settings under qualified physician supervision following individual medical evaluation.

How much does stem cell therapy for cystic fibrosis cost?
Costs vary depending on the individual treatment plan, the number of sessions required, and the method of administration. Detailed, transparent pricing is provided following your medical assessment. All pricing includes evaluation, the procedure itself, and follow-up care.

The information provided on this page is for educational and informational purposes only and should not be construed as medical advice. Stem cell therapy outcomes vary considerably between individuals, and treatment may not be suitable for everyone. Always consult a qualified medical professional before making decisions about your health.